Ipamorelin Compounding Pharmacy: How to Choose a Peptide Compounder

Print or save as PDF

What does FDA's record say about compounded ipamorelin?

Ipamorelin is a five-amino-acid synthetic peptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, that stimulates growth hormone release at the ghrelin/GH-secretagogue receptor rather than the GHRH receptor [1][10]. It was identified in 1998 and developed as an investigational drug for postoperative ileus; that development was reportedly discontinued after disappointing phase 2 results [1][10]. It is not an FDA-approved drug, is not a component of any approved drug, and has no US Pharmacopeia monograph [1].

Three parts of the federal record bear directly on any buying decision.

FDA treats ipamorelin acetate as a significant safety risk. It appears in category 2 for outsourcing facilities. It was added on September 29, 2023 and was still listed on FDA's page dated April 22, 2026 [2][5]. FDA's stated concerns are possible immunogenicity for certain routes from aggregation and impurities, unnatural amino acids that complicate characterization, and a study published in the literature that identified serious adverse events including death when ipamorelin was given intravenously to improve gastric motility; FDA has not identified safety-related information for other injectable routes [2].

The pharmacy-side nominations were withdrawn. For state-licensed pharmacies, ipamorelin appears in the nominated-but-withdrawn table and in none of the three categories on FDA's list updated May 14, 2026, so FDA's category 1 policy does not apply to it [2][11].

The advisory committee voted it down. On October 29, 2024 FDA's Pharmacy Compounding Advisory Committee voted 0 yes, 12 no and 1 abstention on ipamorelin free base, and the same on ipamorelin acetate, citing a lack of information supporting safety and efficacy for growth hormone deficiency and postoperative ileus [3]. FDA reviewers had proposed that it not be added to the pharmacy bulks list [3]. Ipamorelin is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [4].

How do you vet a compounder, given all that?

A pharmacy's paperwork matters less than its honesty about the status above, followed by quality documentation that a licensed compounder should be able to produce.

1. Ask the pharmacy to state ipamorelin's approval status. A pharmacy that calls it FDA-approved, or that claims a pharmacopeial standard, has misstated a documented fact [1].

2. Check the license. Compounding pharmacies are licensed by state boards of pharmacy, and a buyer can check that license directly with the board rather than take it on trust.

3. Ask for a batch-specific certificate of analysis before the vial ships. Not a product specification sheet, but the certificate for the lot you will receive.

4. Ask which laboratory ran the tests. The answer should be specific, and the laboratory should be named on the certificate.

5. Ask where the bulk ipamorelin came from. FDA's category 2 concerns include impurities and aggregation, so the identity and purity of the starting material is a relevant question [2].

6. Match the vial to the certificate. The lot number on the label should match the lot number on the certificate you were given.

7. Ask what patients are told about the GH and IGF-1 axis. FDA says that because ipamorelin stimulates that axis, it may carry the risks listed on approved growth hormone labels: neoplasm, glucose intolerance and diabetes, intracranial hypertension, fluid retention, hypothyroidism, pancreatitis and others, plus possibly QT prolongation as with the approved GH stimulator macimorelin; FDA found no data showing it would not [1].

What should a certificate of analysis cover?

At minimum: identity of the peptide, purity results, sterility testing and endotoxin results, with the methods and testing laboratory named, and a lot number that matches your vial.

That is generic laboratory practice, not an ipamorelin-specific standard. With no USP monograph for ipamorelin, there is no published compendial specification to test the peptide against [1]. FDA has raised concerns about aggregation and peptide-related impurities [2].

What did the human studies actually show?

One published phase 2 trial. Beck and colleagues randomized 117 adults having small or large bowel resection, 114 of whom were analyzed, to intravenous ipamorelin 0.03 mg/kg or placebo twice daily from postoperative day 1 to 7 or discharge [6]. Median time to first tolerated solid meal was 25.3 hours on ipamorelin and 32.6 hours on placebo, a difference that did not reach significance (p=0.15); secondary gastrointestinal recovery endpoints did not differ, and only a subgroup of open-surgery patients showed shorter bowel recovery [6].

Adverse events were common in both arms: 87.5% with ipamorelin versus 94.8% with placebo [6]. Per FDA's summary of the trial, low potassium occurred in 12.5% versus 3.4%, insomnia in 10.7% versus 5.2%, high blood sugar at discharge in 14.3% versus 8.6%, and serious adverse events in 17.9% versus 15.5%. Two ipamorelin-treated patients died of surgical complications after bowel surgery for colon cancer with anastomotic leak; FDA said it is unclear whether the deaths were related to ipamorelin but that they raise safety concerns [1][6].

A separate volunteer study gave healthy men 15-minute intravenous infusions at 4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg and measured pharmacokinetics and growth hormone release. Terminal half-life was about 2 hours, and growth hormone rose in a single peak about 0.67 hours after the infusion and fell to negligible levels at all doses [7]. That study had no efficacy endpoint.

No FDA-approved dose exists. The intravenous regimens above are study doses, not recommendations, and FDA found no human pharmacokinetic, safety or efficacy data for subcutaneous ipamorelin [1][6][7].

What about vials sold as research chemicals?

A research-chemical label does not address FDA's concerns about ipamorelin's aggregation, impurities and characterization [2]. FDA notes ipamorelin has been found in vials confiscated from athletes [1].

Is ipamorelin prohibited in sport?

Yes. WADA names ipamorelin in section S2.2.4 of the 2026 Prohibited List, among growth hormone secretagogues and their mimetics, prohibited at all times in and out of competition and classed as a non-Specified Substance; it also appears in the 2027 list, which takes effect January 1, 2027 [8][9].